Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)

9 november 2026 uppdaterad av: Toby, Inc.

TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds

The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.

Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.

Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.

Studietyp

Observationell

Inskrivning (Beräknad)

30000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: TOBY ATLAS Study Team
  • Telefonnummer: 309-592-8898
  • E-post: info@toby.health

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.

Beskrivning

Inclusion Criteria:

  • Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
  • Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
  • Medical records available for the reference standard.
  • Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.

Exclusion Criteria:

  • Any exclusion stated in the applicable disease specification.
  • Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
  • Current pregnancy, imprisonment, or inability to consent for oneself (consented route).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Target disease cases

Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified.

Controls

Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinical performance of each locked assay
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Paired comparison with available standard-of-care tests
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Assay performance by subgroup and signal origin
Tidsram: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Protocol-conforming specimens with final reference-standard classification
Tidsram: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type.

From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Candidate assays advanced to validation
Tidsram: From study start through study completion, estimated up to 5 years

Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan.

From study start through study completion, estimated up to 5 years
Exploratory prognostic and simulated clinical and economic outcomes
Tidsram: Up to 5 years after specimen collection, where follow-up is permitted and available

Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care.

Up to 5 years after specimen collection, where follow-up is permitted and available

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 januari 2027

Primärt slutförande (Beräknad)

1 januari 2032

Avslutad studie (Beräknad)

1 januari 2032

Studieregistreringsdatum

Först inskickad

4 november 2026

Först inskickad som uppfyllde QC-kriterierna

9 november 2026

Första postat (Faktisk)

12 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

There is currently no plan to make individual participant data available to other researchers.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera